Introduction

Methods
• MEAs represent an avenue for market access for high cost medicines in UK , Italy and Spain. All three countries demonstrate precedence for using MEA's as a mechanism for reimbursing high cost medicines. However, there appear to be very different criteria between UK, Italy and Spain for which products gain MEA's since only 2 products of 68 had an MEA in place in all 3 countries.
• Of the MEA's investigated in UK and Italy, the vast majority of them were for oncology products. In Spain, the MEA's were split across a number of therapeutic areas with the highest numbers in oncology and blood-immunological diseases. For all 3 countries it is apparent that oncology products are most likely to be granted an MEA. This is not surprising as oncology products represent some of the most expensive drugs to launch in recent years.
• The volume of agreements is a lot higher in Italy and UK compared to Spain. This is likely due to the fact that the UK and Italy started negotiating agreements in the last 10 years at a national level and therefore have processes in place for handling these. In contrast, Spain only starting granting the MEA's in 2010, and at a local rather than national level. However, Spain is quickly evolving with the recent national MEA granted in 2013, so we should expect to see the volume of national agreements in Spain increase significantly in the next 2 -3 years.
Conclusion
References: • To assess whether there are any differences in the type of MEAs in the UK, Italy, and Spain in terms of type of agreements and therapy areas covered by these agreements.
• To determine the impact of an MEA in terms of the average market access delay in UK, Italy and Spain.
• To identify any differences in bodies that companies need to negotiate with to get an MEA in these countries (e.g., local, national or regional bodies).
Objectives
• The number of MEAs granted since the year 2000 is much higher in Italy (n=80 risk sharing alone) than in the UK (n=46) or Spain (n=12). In total the 138 agreements covered 68 individual drugs or devices as some of the drugs had MEA's for multiple indications.
• Of the 68 drugs or devices with MEA's in place, only 14 of them had an MEA in place in more than one country. A further two drugs had an MEA in place in all 3 countries investigated (cetuximab and gefitinib -both for oncology indications).
• The UK was the first one to agree to an MEA (pre-2004 . However, the second most frequently therapeutic area was musculoskeletal and ophthalmology in the UK, and opthalmology in Italy. In Spain the two most common therapeutic areas were oncology (25%) and bloodimmunology (25%).
• MEAs' impact on Market Access could only be assessed in the UK. In the UK, MEAs delay the average time of NICE to issue a final decision by up to 10 months depending on the type of MEA (average time when no MEA: 21 months). 
Results
